HIV / AIDS in the News

Number of new HIV infections in Netherlands hasn't declined in five years - NL Times

 

Sister Mary Rose Bernard Groth, 1931-2025: Sister helped fight HIV/AIDS in Papua New Guinea - Toledo Blade

 

Educating The Masses About AIDS/HIV With One Global Event - Los Angeles Sentinel

 

Warning signs of HIV AIDS and 5 doctor-backed tips that can change everything - Times of India

 

Viral infections such as COVID, HIV, can raise heart disease risk, but vaccines may help - Managed Healthcare Executive

 

MSU expert discusses the importance of global HIV efforts - Michigan State University

 

World AIDS Day service to honor theme of ‘Living in a World with HIV’ - Coastal Point

 

Merck’s 2-Drug HIV Regimen Shows Noninferiority to Standard 3-Drug Therapy - Contagion Live

 

Maryland brothers convicted in South Florida black-market HIV drug scheme, feds say - WSVN

 

Merck & Co.'s HIV tablet matches Biktarvy in treatment-naïve patients - FirstWord Pharma

 

Merck’s Two-Drug HIV Regimen Matches Gilead’s Three-Drug Tablet - Merck & Co (NYSE:MRK) - Benzinga

 

Merck Says Its Two-Drug Regimen For HIV Treatment Proven Non-Inferior To Gilead’s Biktarvy In Study - Stocktwits

 

Medicaid: A Lifeline for People Living with HIV - POZ - Health, Life and HIV

 

NMAC Hires Chief Medical Officer To Bridge Public Health Disparities Through Community, Provider, And Policy Education - POZ - Health, Life and HIV

 

Merck's oral HIV treatment non-inferior to Gilead's Biktarvy in late-stage trial - Reuters

 

Merck’s oral HIV treatment meets main goal in late-stage study - The Mighty 790 KFGO

 

As HIV surges, Emory must lead its prevention - The Emory Wheel

 

LGBTQ Agenda: HIV Advocates Blast Delta Air Lines Over PrEP Coverage Hurdles - Lavender Magazine

 

SCOPE: EATG Launches Opportunities to Amplify Community Voices in HIV Prevention - European AIDS Treatment Group

 

HIV fight at risk as Macron expected to skip major health summit - Euractiv

 

Merck's HIV combo matches Gilead's Biktarvy in latest phase 3 test for islatravir - Fierce Biotech

 

Bus stop’s differing visions; HIV cuts; Weekly gun violence report | Morning Roundup - Billy Penn at WHYY

 

Merck's Investigational Drug in Treatment-Naive Adults with HIV-1 Infection Shows Primary Efficacy - MarketScreener

 

Merck (MRK) Shares Positive Phase 3 Trial Results for HIV Treatm - GuruFocus

 

Merck HIV pill matches Gilead’s Biktarvy in trial (MRK:NYSE) - Seeking Alpha

 

Merck’s two-drug HIV regimen shows non-inferiority in phase 3 trial - Investing.com

 

Merck's oral HIV treatment meets main goal in late-stage study - Yahoo

 

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection - Business Wire

 

Clinical spectrum of Talaromyces marneffei infections in HIV-negative patients: an 18-case series including a rare presentation with gastrointestinal onset, adrenal mass, and hemophagocytic lymphohistiocytosis - BMC Infectious Diseases

 

Cryptococcal Meningitis in an HIV-Negative, Lymphoma Survivor: A Case Report of an Uncommon Dual Pathology - Cureus